4 Reasons to Go Long On Kura Oncology Inc. [KURA]

Kura Oncology Inc. [KURA] stock is up 0.05 while the S&P 500 has fallen -0.17% on Friday, 12/04/20. While at the time of this article, KURA ATR is sitting at 2.05, with the beta value at 2.20. This stock’s volatility for the past week remained at 6.06%, while it was 5.50% for the past 30-day period. KURA has risen $0.02 from the previous closing price of $36.80 on volume of 1.3 million shares.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


On 5, December 2020, Kura Oncology Presents First Clinical Data for Menin Inhibitor KO-539 at American Society of Hematology Annual Meeting. According to news published on Yahoo Finance, – Evidence of biologic activity observed in each dose-escalation cohort treated to date –.

Analyst Birdseye View:

The most recent analyst activity for Kura Oncology Inc. [NASDAQ:KURA] stock was on December 03, 2020, when it was Initiated with a Buy rating from Stifel, which also raised its 12-month price target on the stock to $45. Before that, on December 07, 2020, H.C. Wainwright Recapitulated a Buy rating and elevated its amount target to $45. On November 05, 2020, Piper Sandler Downgrade a Neutral rating. On July 07, 2020, Credit Suisse Initiated an Outperform rating and increased its price target to $27. On May 05, 2020, Barclays Initiated an Overweight rating and increased its price target to $24. On July 18, 2019, Deutsche Bank Initiated a Buy rating and boosted its amount on this stock to $28. On November 09, 2018, Piper Jaffray Initiated an Overweight rating. H.C. Wainwright elevated its amount target by recapitulating a higher weight for this stock.

In the past 52 weeks of trading, this stock has oscillated between a low of $6.35 and a peak of $40.62. Right now, the middling Wall Street analyst 12-month amount mark is $43.00. At the most recent market close, shares of Kura Oncology Inc. [NASDAQ:KURA] were valued at $36.82. According to the average price forecast, investors can expect a potential return of 6.47%.


The Principal structure of this organization shows its whole liability to whole principal at 3.42 and the whole liability to whole assets at 3.20. It shows enduring liability to the whole principal at 3.20 and enduring liability to assets at 0.03 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 34.60 points at 1st support level, the second support level is making up to 32.39. But as of 1st resistance point, this stock is sitting at 38.00 and at 39.19 for 2nd resistance point.

Kura Oncology Inc. [KURA] reported its earnings at -$0.42 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.4/share signifying the difference of -0.02 and -5.00% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.4 calling estimates for -$0.42/share with the difference of 0.02 depicting the surprise of 4.80%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for Kura Oncology Inc. [NASDAQ:KURA] is 15.20. Likewise, the Quick ratio is also the same, showing Cash ratio at 15.22. Now if looking for a valuation of this stock’s amount to book ratio is 2.85.

Insider Stories

The most recent insider trade was by FORD KATHLEEN, Chief Operating Officer, and it was the sale of 6250.0 shares on Nov 10. WILSON TROY EDWARD, the President and CEO, completed a sale of 0.11 million shares on Oct 08. On Oct 08, WILSON TROY EDWARD, President and CEO, completed a sale of 50370.0 shares.